Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Potential Pump Malfunction Results In Class I Recall For LifeSPARC Circulatory System

Executive Summary

The US FDA has labelled a recall of several hundred components of the LifeSPARC circulatory support system from LivaNova as class I, the agency’s most serious recall designation.

You may also be interested in...



LivaNova To Buy TandemLife For Up to $250m, Adding Complementary Cardiac Surgery

London-based cardiac surgery and neuroscience group LivaNova PLC is buying privately held Pittsburgh-based TandemLife in a deal worth up to $250m. TandemLife develops advanced cardiopulmonary temporary support systems that are complementary to LivaNova's cardiac surgery segments.

AdvaMed Urges Biden Administration To Use CHIPS To Prioritize Patient Care

Now that the CHIPS and Science Act is law, AdvaMed wants the Biden administration to use it to ensure device makers get the semiconductor chips they need for their products while preventing the US from facing another shortage of the essential components, as experienced during the pandemic.

Compatibility Issues With Some LAV Connectors And Prefilled Syringes Can Interrupt Drug Delivery, FDA Warns

The US FDA says issues with certain LAV connectors attached to prefilled glass syringes may cause clogging and prevent the proper administration of drugs. This could result in serious harm, especially during emergencies.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT145887

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel